Hologic, Inc. (NASDAQ:HOLX)

This womenshealth specialist will benefit from increased emphasis on health in general and womens health, in particular. Unlike the fake claims of Planned Parenthood, HOLX does address relevant issues of womens health. It is pre-eminent in the Liquid Based Pap test arena which is supplanting the classical Pap test and being extended throughout the world as women's rights increase in much of the (non-Muslim) third world. It is also the leader in digital mammography and specialized surgical procedures.

Excellent future prospects.

Specializes in women's health care. Currently exposure to emerging markets is small. There is huge growth opportunity for these products in developing countries like China and Brazil.

2011 Forbes Special Edition

http://news.yahoo.com/s/ap/20110211/ap_on_he_me/us_mammography_device_fda;_ylt=AhNabx_jadN2X5q85vYrZ19v24cA;_ylu=X3oDMTM5cmU3ZDg0BGFzc2V0A2FwLzIwMTEwMjExL3VzX21hbW1vZ3JhcGh5X2RldmljZV9mZGEEY2NvZGUDcmFuZG9tBGNwb3MDNgRwb3MDNgRzZWMDeW5fdG9wX3N0b3JpZXMEc2xrA2ZkYWFwcHJvdmVzZg--

Good Fundamentals, Niche Market

Recently upgraded to Top Pick, for whatever that's worth

Trendspotter

Hologic, the leader in womens healthcare in over nine sectors.. John Cumming was possibly the greatest CEO in womens healthcare and maybe the most successful as well.. Future acquisitions, global expansion, and Tomo approval will help company grow.. I don't see the company continuing like this forever. Rob C. the new Ceo doesnt have the same vision.

low relative PE, good star & 2010 earnings. Bottom fishing week of 11/9

Hopping on with takover rumors should push the stock to at least $25

demand great for product

HOLX

Beaten down over their recent $2.34 billion write-down. Their technology stands as the best in their industry. Quite simply the stock is worth around $19-2o. At such a low price, a buyout seems very plausible given their bondholders current situation.

Stock is down 22% today, giving an excellent entry point. This is an over reaction to a quarterly report in which earnings beat again, and the company delivered $103m FCF despite a strong dollar and weak hospital environment. Overlooked is the continued growth in disposables, high margins, approval of 2 HPV tests (branded as Cervista) which will have a major impact in fiscal 2010. Also awaiting FDA approval is a 3D imaging system called Tomosynthesis, which has enormous potential once hospital budgets free up. The stock is now selling at less than 7x cash flow.

FDA approved two HPV tests. Clinician groups already indicating that these will be required tests.

healthcare $ go to good co's

On 11/18/08, a 5 star stock that is down more than 60 % from its yearly high but recent momentum.

Biotech sector will et a boost from Obama